Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
J Hypertens. 2013 Feb;31(2):321-32. doi: 10.1097/HJH.0b013e32835b50aa.
The present study was performed to investigate in a model of malignant hypertension if the antihypertensive actions of soluble epoxide hydrolase (sEH) inhibition are nitric oxide (NO)-dependent.
ANG II-dependent malignant hypertension was induced through dietary administration for 3 days of the natural xenobiotic indole-3-carbinol (I3C) in Cyp1a1-Ren-2 transgenic rats. Blood pressure (BP) was monitored by radiotelemetry and treatment with the sEH inhibitor [cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyl-oxy]-benzoic acid (c-AUCB)] was started 48 h before administration of the diet containing I3C. In separate groups of rats, combined administration of the sEH inhibitor and the nonspecific NO synthase inhibitor [Nω-nitro-L-arginine methyl ester (L-NAME)] on the course of BP in I3C-induced and noninduced rats were evaluated. In addition, combined blockade of renin-angiotensin system (RAS) was superimposed on L-NAME administration in separate groups of rats. After 3 days of experimental protocols, the rats were prepared for renal functional studies and renal concentrations of epoxyeicosatrienoic acids (EETs) and their inactive metabolites dihydroxyeicosatrienoic acids (DHETEs) were measured.
Treatment with c-AUCB increased the renal EETs/DHETEs ratio, attenuated the increases in BP, and prevented the decreases in renal function and the development of renal damage in I3C-induced Cyp1a1-Ren-2 rats. The BP lowering and renoprotective actions of the treatment with the sEH inhibitor c-AUCB were completely abolished by concomitant administration of L-NAME and not fully rescued by double RAS blockade without altering the increased EETs/DHETEs ratio.
Our current findings indicate that the antihypertensive actions of sEH inhibition in this ANG II-dependent malignant form of hypertension are dependent on the interactions of endogenous bioavailability of EETs and NO.
本研究旨在探讨在恶性高血压模型中,可溶性环氧化物水解酶(sEH)抑制的降压作用是否依赖于一氧化氮(NO)。
通过饮食给予 Cyp1a1-Ren-2 转基因大鼠天然外源性吲哚-3-甲醇(I3C)3 天,诱导 ANG II 依赖性恶性高血压。通过无线电遥测监测血压,并在给予含有 I3C 的饮食前 48 小时开始使用 sEH 抑制剂[顺式-4-[4-(3-金刚烷-1-基-脲基)-环己基氧基]-苯甲酸(c-AUCB)]治疗。在单独的大鼠组中,评估了 sEH 抑制剂和非特异性一氧化氮合酶抑制剂[Nω-硝基-L-精氨酸甲酯(L-NAME)]在 I3C 诱导和非诱导大鼠血压过程中的联合给药。此外,在单独的大鼠组中,联合阻断肾素-血管紧张素系统(RAS)并叠加 L-NAME 给药。经过 3 天的实验方案后,对大鼠进行肾脏功能研究,并测量肾环氧二十碳三烯酸(EETs)及其无活性代谢物二羟二十碳三烯酸(DHETs)的浓度。
c-AUCB 治疗增加了肾脏 EETs/DHETEs 比值,减轻了血压升高,并预防了 Cyp1a1-Ren-2 大鼠中 I3C 诱导的肾功能下降和肾脏损伤的发展。同时给予 L-NAME 完全消除了 sEH 抑制剂 c-AUCB 治疗的降压和肾保护作用,而不改变增加的 EETs/DHETEs 比值,则不能完全挽救双重 RAS 阻断。
我们目前的研究结果表明,在这种依赖 ANG II 的恶性高血压形式中,sEH 抑制的降压作用依赖于内源性 EETs 和 NO 的生物利用度相互作用。